ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene

被引：0
|
作者：
Isozaki, Hideko [1 ]
Ichihara, Eiki [1 ]
Yasugi, Masayuki [1 ]
Nobuaki, Ochi [2 ]
Hotta, Katsuyuki [1 ]
Takigawa, Nagio [2 ]
Sendo, Toshiaki [1 ]
Tanimoto, Mitsune [1 ]
Kiura, Katsuyuki [1 ]
机构：
[1] Okayama Univ, Okayama 7008530, Japan
[2] Kawasaki Med Sch, Okayama, Japan
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3721
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer
    Hui, Beina
    Zhang, Jingping
    Shi, Xiaobo
    Xing, Fangfang
    Shao, Yang W.
    Wang, Yuanyuan
    Zhang, Xiaozhi
    Wang, Shuwen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1470 - 1474
  • [42] Detection of EML4-ALK and Other ALK Fusion Genes in Lung Cancer: A Lesson from the Leukemia Fusion Gene Analysis and Future Application
    Park, Tae Sung
    Jeon, You La
    Lee, Hee Joo
    Jeong, Jae-Heon
    Kim, Si Young
    Cho, Eun Hae
    Marschalek, Rolf
    Meyer, Claus
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (05) : 576 - 577
  • [43] Clinical Aspects Of Non-Small Cell Lung Cancer Harboring Eml4-Alk Fusion Gene In Tohoku University Hospital
    Sakakibara, T.
    Inoue, A.
    Fukuhara, T.
    Sasaki, T.
    Nukiwa, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [44] Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
    Guo, Weihong
    Liang, Jianping
    Zhang, Dandan
    Huang, Xikun
    Lv, Yanhua
    MEDICINE, 2022, 101 (40) : E30913
  • [45] Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein
    Kawamura, Takahisa
    Murakami, Haruyasu
    Kobayashi, Haruki
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (01) : 184 - 187
  • [46] Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant
    Song, Peng
    Zhang, Jingcheng
    Shang, Congcong
    Zhang, Li
    THORACIC CANCER, 2018, 9 (10) : 1327 - 1332
  • [47] Outcome of two patients harboring EML4-ALK fusion gene with brain metastasis treated with crizotinib
    Okimoto, Tamio
    Tsubata, Yukari
    Nakao, Mika
    Koba, Naoya
    Hotta, Takamasa
    Hamaguchi, Megumi
    Hamaguchi, Shunnichi
    Sutani, Akihisa
    Hamada, Akinobu
    Isobe, Takeshi
    ANNALS OF ONCOLOGY, 2015, 26 : 137 - 138
  • [48] Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein
    Takahisa Kawamura
    Haruyasu Murakami
    Haruki Kobayashi
    Kazuhisa Nakashima
    Shota Omori
    Kazushige Wakuda
    Akira Ono
    Hirotsugu Kenmotsu
    Tateaki Naito
    Masahiro Endo
    Toshiaki Takahashi
    Investigational New Drugs, 2019, 37 : 184 - 187
  • [49] A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib
    Shen, Qian
    Kalyani, Farhin Shaheed
    Qu, Jingjing
    Chen, Zhen
    Zhang, Jing
    Zhou, Jianying
    CLINICAL LUNG CANCER, 2021, 22 (06) : E799 - E803
  • [50] Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
    Emily K. Kleczko
    Trista K. Hinz
    Teresa T. Nguyen
    Natalia J. Gurule
    Andre Navarro
    Anh T. Le
    Amber M. Johnson
    Jeff Kwak
    Diana I. Polhac
    Eric T. Clambey
    Mary Weiser-Evans
    Daniel T. Merrick
    Michael C. Yang
    Tejas Patil
    Erin L. Schenk
    Lynn E. Heasley
    Raphael A. Nemenoff
    npj Precision Oncology, 7
12345